Page results
-
RESPOND – Information for healthcare professionals and services working with asylum seekers
-
Information about the Therapeutic Plasma Exchange at NHNN for patients, carers, and families.
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
-
Nine Covid-19 research studies are already taking place at UCLH and the Trust is processing more than 30 study proposals as research efforts around the virus and pandemic are ramped up.
-
Read more about a UCLH patient saved by special 'before midnight' transfusions.
-
Read more about the NHS Staff Survey 2024 - we’re the top acute trust to work at for third year running!
-
UCLH is continuing to scale up the number of services that offer Advice & Guidance, as well as identifying various improvements within the existing Advice & Guidance service. Over the last few months, UCLH has introduced 5 new specialties to the service, with additional specialties due to go live shortly.
-
UCLH will play a vital role in a new respiratory virus study.
-
People with the acquired communication disorder aphasia – which involves problems with the understanding or production of speech –have benefitted greatly from a two-year programme of therapy at the National Hospital for Neurology and Neurosurgery at UCLH.
-
Holistic Needs Assessment (HNA): Information for people affected by cancer and blood conditions patient information leaflet
File results
-
FOI/2024/0134 - Joint infection services for paediatric/ adult patients
-
FOI/2024/0136 - Female Genital Mutilation (FGM) cases from 2014-February 2024
-
FOI/2024/0140 - Operations cancelled due to low levels of staffing 2019-2023
-
FOI/2024/0143 - Individuals arriving at A&E not in an ambulance
-
FOI/2024/0144 - Breast cancer treatment
-
FOI/2024/0148 - Cleaning audit system at Trust
-
FOI/2024/0149 - National Hospital for Neurology and Neurosurgery (NHNN) admissions 2018-2023
-
FOI/2024/0155 - Immunotherapy treatments for lung cancer
-
FOI/2024/0162 - Various technology systems/ services used at Trust
-
FOI/2024/0163 - Renal cell carcinoma and melanoma treatments